![[116] New drug for cystic fibrosis: Regulatory approval, clinical uncertainty?](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2018/12/116-150x150.png)
A new drug for cystic fibrosis (CF) that combines lumacaftor and ivacaftor (Orkambi), was approved by Health Canada (HC) in 2016 to treat people age 12 and older with the most frequent CF genetic mutation: homozygous F508 deletion of the cystic … Read More
What’s New
![[115] Cannabinoids for Chronic Pain](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2018/11/115-150x150.png)
[115] Cannabinoids for Chronic Pain
Canada's parliament legalized the recreational use of herbal cannabis (marijuana) in October 2018. The well-publicized limitations of clinical research and well-recognized side effects such as cannabis intoxication have not deterred people from … Read More
30th Annual Best Science Medicine Course
Friday, May 3, 2019 and Saturday, May 4, 2019 Fairmont Waterfront – 900 Canada Place Way, Vancouver, BC … Read More
![[114] Shingrix: A New Vaccine for Shingles](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2018/10/114-150x150.png)
[114] Shingrix: A New Vaccine for Shingles
Herpes zoster (HZ) or “shingles” occurs when the varicella zoster virus (VZV), lying latent in the sensory ganglia, becomes reactivated. An HZ outbreak typically presents as a vesicular skin eruption most characteristically forming a painful girdle … Read More
![[113] How well do you know your anticholinergic (antimuscarinic) drugs?](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2018/09/113-150x150.png)
[113] How well do you know your anticholinergic (antimuscarinic) drugs?
Anticholinergic drugs, prescribed for a variety of clinical conditions, are amongst the most frequently used prescription drugs in BC (Table 1). Also referred to as “antimuscarinics,” such drugs specifically block muscarinic receptors for … Read More
